tiprankstipranks
Advertisement
Advertisement

CELC Stock Latest News

Positive VIKTORIA-1 Phase 3 Results and Competitive Profile Drive Buy Rating and Upward Price Target Revision to $165
RatingsPositive VIKTORIA-1 Phase 3 Results and Competitive Profile Drive Buy Rating and Upward Price Target Revision to $165
2d ago
CELC
Celcuity Reports Positive Phase 3 Results for Gedatolisib
PremiumCompany Announcements
Celcuity Reports Positive Phase 3 Results for Gedatolisib
2d ago
8K
CELC
Celcuity trading resumes
PremiumThe Fly
Celcuity trading resumes
2d ago
CELC
Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint
PremiumThe Fly
Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint
2d ago
CELC
Celcuity trading halted, news pending
PremiumThe Fly
Celcuity trading halted, news pending
3d ago
CELC
Celcuity initiated with an Outperform at Citizens
PremiumThe FlyCelcuity initiated with an Outperform at Citizens
7d ago
CELC
Celcuity’s Earnings Call: Big Data, Bigger Ambitions
Premium
Company Announcements
Celcuity’s Earnings Call: Big Data, Bigger Ambitions
1M ago
CELC
Celcuity Buy Rating Backed by Strong Gedatolisib Data, Upcoming VIKTORIA-1 Catalyst, and Favorable Risk-Reward
Premium
Ratings
Celcuity Buy Rating Backed by Strong Gedatolisib Data, Upcoming VIKTORIA-1 Catalyst, and Favorable Risk-Reward
1M ago
CELC
Celcuity price target raised to $141 from $108 at Craig-Hallum
PremiumThe Fly
Celcuity price target raised to $141 from $108 at Craig-Hallum
1M ago
CELC
Celcuity: Clinical Momentum, Strong Balance Sheet, and Regulatory Catalysts Underpin Buy Rating and $122 Target
PremiumRatings
Celcuity: Clinical Momentum, Strong Balance Sheet, and Regulatory Catalysts Underpin Buy Rating and $122 Target
1M ago
CELC
Celcuity price target raised to $125 from $115 at Stifel
PremiumThe Fly
Celcuity price target raised to $125 from $115 at Stifel
1M ago
CELC
Celcuity (Giredestrant): Anticipated PIK3CA Data and Global Regulatory Momentum Support Buy Rating
PremiumRatings
Celcuity (Giredestrant): Anticipated PIK3CA Data and Global Regulatory Momentum Support Buy Rating
1M ago
CELC
Closing Bell Movers: Navan jumps over 20% after results
PremiumThe FlyClosing Bell Movers: Navan jumps over 20% after results
1M ago
GO
WS
Celcuity reports Q4 EPS (73c), consensus ($1.01)
Premium
The Fly
Celcuity reports Q4 EPS (73c), consensus ($1.01)
1M ago
CELC
Is CELC a Buy, Before Earnings?
Premium
Pre-Earnings
Is CELC a Buy, Before Earnings?
2M ago
CELC
Celcuity: Undervalued Pipeline with Differentiated Clinical Profile Supports Buy Rating
PremiumRatings
Celcuity: Undervalued Pipeline with Differentiated Clinical Profile Supports Buy Rating
2M ago
CELC
Celcuity price target raised to $122 from $95 at Needham
PremiumThe Fly
Celcuity price target raised to $122 from $95 at Needham
2M ago
CELC
Celcuity (CELC): Strengthened Gedatolisib Data and Priority Review Drive Reiterated Buy Rating and Higher Price Target
PremiumRatings
Celcuity (CELC): Strengthened Gedatolisib Data and Priority Review Drive Reiterated Buy Rating and Higher Price Target
2M ago
CELC
Celcuity reports results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 trial
PremiumThe Fly
Celcuity reports results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 trial
2M ago
CELC
Celcuity Adds Veteran Director to Strengthen Oncology Strategy
PremiumCompany AnnouncementsCelcuity Adds Veteran Director to Strengthen Oncology Strategy
3M ago
8K
CELC
Short Report: Celcuity short interest continues to grow
Premium
The Fly
Short Report: Celcuity short interest continues to grow
3M ago
RDW
CELC
Celcuity announces FDA accepted for filing its NDA for gedatolisib
Premium
The Fly
Celcuity announces FDA accepted for filing its NDA for gedatolisib
3M ago
CELC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >